Microbes have survived over billions of years and continue to evolve to resist human attempts to kill them. In 2019, over 1.2 million people died as a direct result of antimicrobial resistance (AMR). The World Health Organization (WHO) predicts this to increase tenfold by 2050.
Global efforts are emerging to address the funding, pricing, and manufacturing of new antibiotics, but that alone won’t fix the problem as in time, microbes will resist those too. However, Jiaxi Liu, investment analyst for Baillie Gifford’s Health Innovation Fund, says there is a glimmer of hope. New approaches and tools are already shaking up antimicrobial innovation and could set us on the correct course to solve the broader AMR crisis. These include:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze